6Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis[J]. Clin Infect Dis, 2004,38:161 -189.
7Wong-beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges[J]. Pharmacotherapy, 2003,23:1441 - 1462.
8Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[ J].N Engl J Med,2002,347:408-415.
9Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer[J]. Clin Infect Dis,2002,34:730 -751.
10Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J]. N Engl J Med,2002,346: 225 - 234.
二级参考文献1
1[1]Liebowitz LD, Ashbee HR, Evans EG, et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion[J]. Diagn Microbiol Infect Dis, 2001, 40: 27-33
6Habicht JM, Preiss M, Passweg J, et al. Invasive pulmonary aspergillosis: effects of early resection in a neutropenic rat model[ J]. Eur J Cardiothorac Surg, 2002, 22(5):728- 732.
7Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis [ J]. Methods Mol Med, 2005,118 : 129 - 142.
8Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis[J]. Clin Microbiol Infect, 2004, 10(10) : 925 - 928.
9Sheppard DC, Rieg G, Chiang LY, et al. Novel inhalational routine model of invasive pulmonary aspergillosis [ J ]. Antimicrob Agents Chemother, 2004, 48(5):1908- 1911.
10Steinbach WJ, Benjamin DK Jr, Trasi-SA, et al. Value of an inhalational model of invasive aspergillosis [ J ]. Med Mycol, 2004, 42(5) :417 - 425.
